- About Us
Dr. Alfred Botchway is currently the Interim President and CEO of BioKansas, a 501(c)(3) trade organization and voice of the bioscience community in Kansas. Alfred was appointed the Interim President, after having served as Board Chair of BioKansas as well as for numerous years on the Board of Directors.
Dr. Alfred Botchway is also the Chief Relationship Officer at QA Compliant, Inc. a quality assurance company established to support the Biotechnology, Pharmaceutical and Agrochemical industry in its highly regulated environment.
In 2006, Dr. Botchway founded and was the CEO of Xenometrics, LLC a nonclinical contract research laboratory which focused on assessing the safety profile of pharmaceutical, biotechnological, agrochemical products and medical devices. Alfred has ample years of experience spanning academic research, a major pharmaceutical company and a contract laboratory, consequently retaining extensive insight into drug and/or chemical development. Alfred’s experience includes developing cost effective methods, managing multi-million dollar budgets, and extensive research in safety pharmacology/Toxicology with particular emphasis on arrhythmogenic activities, along with pharmacokinetic/pharmacodynamics interactions. Dr. Alfred Botchway served as the President of the International Safety Pharmacology Society in 2015, after having been on the Board of Directors for over 5 years. In addition to his scientific endeavors, he also served on the State of Kansas’s Council of Economic Advisors. Alfred graduated from Pipeline (an Entrepreneurial Immersion Program), and was elected the first President of the Alumni and served on the Pipeline Board of Directors for numerous years. After Xenometrics was acquired in Q4 of 2017, Alfred remained with the organization for over a year as part of the Executive team furthering the growth of the Kansas City site as well as assisting with strategic planning for seven other global sites. Alfred eventually executed his succession plan, and transitioned the organization that he founded to new shareholders. Dr. Alfred Botchway is an investor in his own right and remains an active angel investor.
Alfred holds a BSc and an MSc in Biomedical Science from the University of Kingston, Surrey, UK and the North East College of Technology, Surrey, UK, respectively. By virtue of his masters (hematology major), he developed a keen interest in cardiovascular physiology. Subsequent to a special interest and research in electrophysiological changes associated with regression of left ventricular hypertrophy, Alfred was awarded a Ph.D. from the Imperial College of Science, Technology and Medicine, London, UK.